Rapid Responses to:

LETTERS: Leslie L Citrome Efficacy should drive atypical antipsychotic treatment BMJ 2003; 326: 283a [Full text]

Rapid Responses: Submit a response to this article

Rapid Responses published:

Efficacy should drive atypical antipsychotic treatment

Eileen McGinn   (23 September 2003)

Efficacy should drive atypical antipsychotic treatment 23 September 2003
Eileen McGinn, MPH New York New York 10003 Send response to journal: Re: Efficacy should drive atypical antipsychotic treatment	People with schizophrenia have two to four times the rate of diabetes as the general population, prior to any treatment with psychotropic drugs. In addition, most studies show a similar effectiveness of typical and atypical drugs. Atypicals are being promoted because of their benign profile, which has to do with reduced EPS. Recent research has shown that atypicals are associated with insulin resistance, etc. Their profile can no longer be considered benign, but rather to have different concerns, namely metabolic problems. Competing interests:   None declared